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Introduction
The manual has been prepared by the Expert Team 
of the Polish Menopause and Andropause Society 
(PTMA) for physicians representing various medical 
specialties who see patients with menopausal symp-
toms in their daily practice. The manual is based on 
the most up-to-date recommendations and consensus 
statements of different expert groups representing 
a number of highly reputable institutions including Na-
tional Institute for Health and Care Excellence (NICE), 
North American Menopause Society (NAMS), Interna-
tional Menopause Society (IMS), American College of 
Endocrinology (ACE), Polish Society of Gynecologists 
and Obstetricians (PTGiP), Polish Cardiac Society (PTK) 
or PTMA. In order to make the manual as practical as 
possible, we have decided to present the current state 
of knowledge on menopausal hormone therapy (MHT) 
in the form of questions and answers. They address 
issues which are essential for initiating and manag-
ing MHT based on the most up-to-date treatment al-
gorithms and, at the same time, in line with the old 
maxim “primum non nocere”.
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Abstract
This manual has been prepared by the Expert Team of the Polish Menopause and Andropause Society for 
physicians representing various medical specialties who see patients with menopausal symptoms in their daily 
practice. In order to make the manual as practical as possible, the current state of knowledge on menopausal 
hormone therapy (MHT) is presented in the form of questions and answers. They address issues which are es-
sential for initiating and managing MHT based on the most up-to-date treatment algorithms and, at the same 
time, in line with the old maxim “primum non nocere”. 
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What is the aim of menopausal hormone 
therapy?
The primary aim of menopausal hormone therapy 
(MHT) is to improve women’s quality of life by relieving or 
eliminating menopausal symptoms.
Menopausal hormone therapy is an individual choice 
motivated by improvement in the quality of life and health 
priorities, and involving multiple additional factors such as 
age, time since the last menstruation, risk of venous throm-
boembolism (VTE), stroke, ischemic heart disease and 
breast cancer. The decision to start therapy and the selec-
tion of treatment modality should be individualized, taking 
into account the woman’s quality of life and priorities as 
well as specific risk factors and potential threats.
What are the indications for menopausal 
hormone therapy?
The indications to initiate MHT are listed below.
1.  Menopausal symptoms, primarily moderate and se-
vere vasomotor symptoms.
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2.  Symptoms of genitourinary syndrome of menopause 
(GSM) – typically vaginal dryness, pollakiuria, noc-
turia, urinary urgency, recurrent vaginitis and cysti-
tis. Both systemic and topical estrogen treatments 
are effective. In some cases, the concurrent use of 
both routes of estrogen administration is justified. If 
symptoms of urogenital atrophy are the only reason 
for starting MHT, or if systemic hormone treatment is 
contraindicated, topical estrogen therapy is recom-
mended.
3.  Primary ovarian insufficiency: premature and early 
menopause – treatment should be continued until at 
least 51 years of age.
4.  Osteoporosis – prevention and treatment, particu-
larly until the age of 60 years. The therapeutic man-
agement is effective in preventing bone mass loss 
(also at ultra-low doses) and reducing the incidence 
of fractures – including vertebral and hip fractures 
(at a standard dose). The effect is sustained only for 
the duration of estrogen administration. After the 
discontinuation of treatment, accelerated bone mass 
loss typical of the menopause is observed.
5.  Prevention of systemic disorders associated with 
estrogen deficiency which increase in the postmeno-
pausal period. Reduced risk of cardiovascular diseas-
es, diabetes, metabolic syndrome, Alzheimer’s dis-
ease and Parkinson’s disease, provided that therapy 
is initiated in the perimenopausal period or during 
the first few years after the last menstruation.
What is the effect of menopausal hormone 
therapy on the brain?
All brain structures and functions are estrogen-sensi-
tive. Estrogens have a protective effect on the neurons. 
The latter activity of estrogens is based on reducing 
oxidative stress, promoting the formation of new neu-
rons and synapses, and enhancing the ability to remodel 
and repair brain structures or brain damage. Estrogens 
regulate the bioenergetic system of the brain: estradiol 
increases glucose uptake and sustains the process of en-
ergy use from glucose in the brain. Estrogen deficiency 
induces the so-called hypometabolic state of the brain 
associated with inadequate supply of glucose and the 
need to derive energy from lipid metabolism, promoting 
the development of Alzheimer’s disease. 
What is the effect of menopausal hormone 
therapy on metabolism?
Estradiol increases the uptake of glucose by various 
tissues. The administration of the hormone increases 
insulin sensitivity. The concentrations of glucose, in-
sulin and lipids in diabetic women receiving hormone 
therapy during the menopause are closer to the norm 
than in women who do not take hormones.
Estrogens play a major role in the body’s energy me-
tabolism also by affecting the hypothalamic neurons. They 
stimulate the appetite suppressing center and suppress 
the appetite center. They affect the distribution of body fat. 
Women with estrogen deficiency are more susceptible to 
gain weight and an increase in abdominal fat accumulation. 
Estrogen deficiency leads to post-menopausal weight gain.
Do estrogens have a cardioprotective 
effect?
Estrogen therapy initiated during the so-called 
optimum therapeutic window (i.e. < 60 years of age or 
< 10 years after the last menstruation) produces a ben-
eficial effect on vascular function, cholesterol concen-
tration and carbohydrate metabolism, which lowers the 
incidence of coronary episodes and myocardial infarc-
tions, and reduces total mortality. However, the initia-
tion of MHT in women older than 60 years of age or 
> 10 years after the last menstruation may lead to an 
increased incidence of coronary episodes, particularly 
during the first two years of treatment.
What is the role of menopausal hormone 
therapy in the prevention and treatment  
of osteoporosis?
Menopausal hormone therapy is an effective and 
appropriate modality for preventing osteoporotic frac-
tures in women under the age of 60 years or within 
10 years after the last menstruation.
Menopausal hormone therapy is the first-line man-
agement for the prevention and treatment of osteopo-
rosis in women with premature menopause, and until 
60 years of age. Standard-dose estrogen therapy re-
duces the risk of vertebral and hip fractures and other 
extravertebral fractures. Low and ultra-low doses of es-
trogens, regardless of the route of administration, show 
a  positive effect on bone mass density. The effect is 
sustained during the entire period of supplementation, 
and it subsides after the discontinuation of therapy.
What are the absolute contraindications 
to systemic menopausal hormone therapy?
Based on the most up-to-date recommendations 
the absolute contraindications to MHT include:
•	 pregnancy,
•	 undiagnosed abnormal uterine bleeding,
•	 high risk of venous thromboembolism,
•	 inadequately controlled arterial hypertension,
•	 past history of myocardial infarction, stroke or unsta-
ble coronary disease,
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•	 active liver disease, liver failure,
•	 active or past history of estrogen-related cancer.
A contraindication to progestogen therapy is men-
ingioma.
Is menopausal hormone therapy 
associated with an increased risk  
of breast cancer?
The potential increase in breast cancer risk as-
sociated with estrogen/progestogen therapy is small 
(< 1 case/1,000 women/year), comparable to the risk 
induced by a post-menopausal weight gain of 5 kg or 
regular consumption of strong alcoholic beverages. 
A very important role seems to be played by progesto-
gen and its administration regimen. The most favorable 
safety profile has been demonstrated for progesterone 
and dydrogesterone, and sequential therapy has been 
shown as superior to the continuous regimen. 
Based on the current state of knowledge, MHT is 
not indicated in women after breast cancer treatment. 
What is the effect of menopausal 
hormone therapy on the risk of venous 
thromboembolism and ischemic stroke?
Venous thromboembolism is one of the two major 
complications potentially occurring during MHT. The 
risk increases with women’s age, BMI (> 30 kg/m2 – 
a nearly threefold increase) and estrogen dose, and it 
is the highest during the first year of therapy. A WHI 
trial has shown additional 11 cases/10,000 women for 
the estrogen/progestogen therapy, and 4 additional 
cases/10,000 women in the age range of 50-59 years 
taking estrogens alone.
The risk of VTE and ischemic stroke increases in pa-
tients using oral MHT, but the absolute risk in women 
under 60 years of age is low. A lower risk, or likely ab-
sence of risk increase, has been shown for transdermal 
therapy.
Blood coagulation tests for thrombophilia may be 
recommended in patients with a positive personal and 
family history.
What are the most common reasons 
for menopausal hormone therapy 
discontinuation?
Only 1 in 5 women starting MHT continue the treat-
ment for more than 2 years. The most common adverse 
reaction and, at the same time, the most frequent 
reason for early discontinuation of MHT is abnormal 
uterine bleeding occurring particularly during continu-
ous combined therapy. Although the symptom is usu-
ally transient and carries no risks, it is responsible for 
the discontinuation of hormone therapy in almost one 
in every two cases. There are many reasons for abnor-
mal uterine bleeding during MHT, the most common of 
which are:
•	 patient’s incorrect use of MHT,
•	 lack of synchronization with endogenous ovarian 
function,
•	 suboptimal E + P combination (e.g. excessive dose 
of estrogen, continuous regimen in a premenopausal 
patient or shortly after the menopause),
•	 endometrial atrophy,
•	 previously undiagnosed organic abnormalities such 
as endometrial polyp, endometrial hyperplasia/can-
cer, uterine fibroids or vaginitis atrophica.
What is the recommended duration  
of menopausal hormone therapy?
The duration and dose of MHT should be individ-
ualized depending on the goals of therapy and safety 
concerns.
The lowest effective estrogen dose should be pre-
scribed. Most up-to-date recommendations do not im-
pose any arbitrary restrictions on the duration of MHT. 
The continuation of treatment depends on the patients’ 
health status and individual risk profile, and the deci-
sions made by informed patients. According to PTMA 
experts longer MHT is possible depending on the wom-
an’s symptoms and/or preferences, when individual 
long-term benefits associated with improved quality 
of life and reduced risk of chronic diseases outweigh 
potential risks.
The discontinuation of treatment may be considered 
in cases of contraindications to MHT, lack of patient ac-
ceptance or inability to perform follow-up examinations 
which are essential for safe continuation of treatment.
If the patient’s sole motivation to start MHT is the 
elimination of climacteric symptoms, the only way to de-
termine whether the therapy should be continued is tem-
porary discontinuation of hormonal supplementation fol-
lowed by the patient’s self-assessment of the severity of 
menopausal complaints or objectivized evaluation using 
a validated scale (e.g. Greene Climacteric Scale). A recur-
rence of menopausal symptoms causing impaired quality 
of life represents an indication to resume MHT.
What is the recommended starting dose of 
estradiol in menopausal hormone therapy?
Menopausal hormone therapy can be used at stan-
dard, low or ultra-low doses. In consideration of the 
risk of adverse reactions the goal should be to use the 
lowest individually adjusted effective hormone doses. 
Based on the current state of knowledge, the standard 
dose is 2 mg of estradiol (E
2) for oral administration 
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and 50 µg of E2 for transdermal administration. The low 
dose is 1 mg of E2 for oral administration or 25-37.5 µg 
of E2 for transdermal administration. The ultra-low dose 
is 0.5 mg of E2 for oral administration or 14 µg of E2 
for transdermal administration. The simplest method 
of evaluating the efficacy of treatment is the wom-
an’s response and the degree of elimination of existing 
menopausal symptoms depending on the dose during 
the first 2-3 months. A clear correlation is observed be-
tween the dose of estrogens and the degree of elim-
ination/relief of menopausal symptoms. The lowest 
dose causing a statistically significant reduction in the 
frequency of hot flushes is the ultra-low estradiol dose 
of 0.5 mg. Further dose reductions result in the loss of 
therapeutic effect.
The therapeutic dose can also depend on the pa-
tient’s age and type of menopause (natural vs. sur-
gical). Younger women more commonly need higher 
doses, whereas postmenopausal patients usually note 
an improvement after using low or ultra-low doses of 
estrogens.
An appendix to this manual contains a list of drugs 
for estrogen-progestogen MHT which are available in 
Poland. The drugs are sorted by the dose of estrogens 
in their composition.
What is the role of the route of hormone 
administration in menopausal hormone 
therapy?
Hormone substitution can be administered orally, 
transdermally, intramuscularly and intravaginally. How-
ever, subcutaneous estradiol implants and estradiol- 
releasing vaginal rings are currently unavailable in Po-
land. Progestogen can also be administered directly 
into the uterine cavity via levonorgestrel intrauterine 
systems (LNG-IUS). Hormones are most commonly 
taken via the oral route. Oral administration is asso-
ciated with a more prominent beneficial effect on the 
parameters of lipid metabolism, but at the same time 
it is a more common trigger of thromboembolic com-
plications.
Transdermal MHT can be administered in the form 
of skin patches, gels or sprays. Transdermal patches 
available in Poland contain estradiol alone or in combi-
nation with norethisterone acetate, and can be used in 
sequential or continuous treatment regimens. Gels and 
sprays available in Poland contain estradiol alone.
On the Polish market, there is also one product 
containing estradiol and prasterone sulfate (precursor 
for dehydroepiandrosterone synthesis) intended for in-
tramuscular administration every 4-6 weeks. As in the 
case of oral products containing estradiol alone, the 
product should be supplemented with progestogen in 
women with preserved uterus.
There are a number of medical conditions justifying 
the use of transdermal or intramuscular dosage forms, 
including diseases of the liver, biliary and digestive sys-
tems, thyroid disorders, hypertension, hypertriglycer-
idemia, and polypragmasia. Transdermal therapy has 
not been found to increase the risk of thromboembolic 
complications or mammographic density.
What is the role of progestogen selection 
in combined menopausal hormone 
therapy?
Progestogens are used in MHT solely to prevent en-
dometrial hyperplasia. Hysterectomized women should 
receive estrogens alone. Combined estrogen-progestin 
therapy involves a slightly higher risk of breast cancer 
and has a reduced cardioprotective effect. The choice of 
progestogen type and route of administration depends 
on the metabolic safety profile and the patient’s person-
al preferences. Progesterone- or dydrogesterone-based 
MHT is the most metabolically beneficial treatment mo-
dality. In addition, it is associated with the lowest risk 
of breast cancer. Testosterone-derived progestogens 
have a positive effect on bone mass density. There are 
reports suggesting that progestogens belonging to this 
group may enhance the quality of sexual life. Progesto-
gens with antiandrogenic activity are prescribed in the 
treatment of hirsutism in women.
What aspects should be considered for the 
selection of menopausal hormone therapy 
regimen?
Women with preserved uterus can use MHT consist-
ing of estrogen and progestogen administered in a se-
quential or continuous regimen. The selection of deliv-
ery regimen is independent of the route of hormone 
administration.
The sequential regimen may involve drug adminis-
tration for 21 days: initially estrogens alone, followed 
by estrogens combined with progestogen for the re-
maining 10-12 days. The 7-day break in hormone use 
causes a  withdrawal bleed. This therapeutic regimen 
is beneficial only during the early perimenopause. 
Because of a marked decrease in estrogen concentra-
tion and climacteric symptoms occurring occasion-
ally towards the end of the 7-day break, the regimen 
commonly used from the late menopause is based on 
continuous administration of estrogens combined with 
a 12-14 day progestogen course. As soon as one pack 
of the drug is used, the next pack should be started. 
Progestogen withdrawal bleeding usually occurs during 
the first days after starting a new pack of the drug. Also, 
it may be acceptable to extend the period of treatment 
with estrogens alone and induce bleeding on a two- or 
three-monthly basis.
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Sequential regimens are most typically prescribed 
to women with premature loss of ovarian function and 
to patients during the perimenopausal period.
The continuous regimen involves the concurrent 
administration of estrogen and progestogen, usually at 
lower single doses. Consequently, continuous admin-
istration of progestogens causes endometrial atrophy, 
which stops withdrawal bleeding. However, the risk of 
uncontrolled uterine spotting must be considered. Even 
though the frequency of spotting episodes decreases 
with therapy, it must be noted that the elimination of 
bleeding in continuous therapy is difficult to achieve in 
women during the perimenopausal period, with uterine 
fibroids or history of profuse menstrual bleeding, and 
treated with drugs affecting the coagulation system 
(anti-coagulation and anti-aggregation agents).
The continuous regimen is prescribed to patients 
who no longer want uterine bleeding, in the postmeno-
pausal period, preferably at least a year after the last 
menstruation. Women who want to maintain uterine 
bleeding and patients who do not accept spotting as-
sociated with continuous therapy can be prescribed se-
quential MHT in the postmenopausal period.
The essential factor in MHT selection should be in-
dividualization – adjustment of therapy to the woman’s 
needs, risk factors and personal preferences.
What examinations should be performed 
before the start of menopausal hormone 
therapy?
1. Personal medical history (diseases, surgical proce-
dures, medications, obstetric history including ges-
tational hypertension, preeclampsia, gestational di-
abetes) and patient’s family history (cancer, arterial 
and venous vascular diseases).
2. Physical examination with measurements of body 
weight and BMI, arterial blood pressure and waist-
hip ratio (if required).
3. Gynecological examination with cytological smear for 
cancer screening and transvaginal ultrasound scan.
4. Palpatory breast examination and verification of 
most recent results of imaging examinations (mam-
mography and/or ultrasonography). Recent mam-
mography or breast ultrasound results do not ab-
solve the physician from the obligation to perform 
a palpatory examination.
5. Determination of fasting glucose and total cholester-
ol concentrations, and in patients with risk factors or 
abnormalities – oral glucose tolerance test (OGTT), 
preferably with lipid profile.
6. In uncertain cases, an assessment (even repeated) of 
the follicle-stimulating hormone (FSH) and estradiol 
concentrations, and in selected cases also the anti- 
Müllerian hormone (AMH) concentration (in hys-
terectomized women or in patients using hormonal 
contraception or other hormonal therapies).
7. In selected clinical situations, the spectrum of exam-
inations may be extended to include the assessment 
of TSH, transaminases, bilirubin or coagulation system 
parameters, abdominal ultrasound imaging, evaluation 
of the venous system of the lower extremities, exam-
ination of carotid arteries, densitometry or assessment 
of genetic predisposition to breast and ovarian cancer. 
In the majority of patients there is no need to perform 
the examinations listed above before initiating MHT.
What follow-up examinations should be 
performed during menopausal hormone 
therapy and at what frequency?
The first follow-up examination should be scheduled 
after 3 to 4 months of therapy. The aim is to review the ef-
ficacy of treatment and discuss side effects, adjust treat-
ment components, doses or route of administration, and 
address any concerns the patient may have. Every woman 
receiving MHT should undergo follow-up examinations 
once a  year as a  minimum. After taking the patient’s 
history and a  general physical examination followed by 
blood pressure and body weight measurements, the pa-
tient should undergo a gynecological examination. Cyto-
logical tests for cancer screening should be repeated on 
a three-yearly basis in low-risk groups, and once a year in 
patients with increased risk. Transvaginal ultrasound scan 
is not necessary in patients with normal pattern and se-
verity of bleeding in sequential therapy or no bleeding in 
continuous therapy. Every patient should undergo a palpa-
tory breast examination on a yearly basis, and should be 
referred for breast imaging examinations. The basic exam-
ination recommended for diagnostic breast cancer screen-
ing is mammography, however if mammographic findings 
suggest higher sensitivity of ultrasonographic diagnostic 
techniques, mammography can be substituted by or com-
bined with sonographic examination.
The frequency of follow-up laboratory tests depends on 
the results of preliminary examinations. It should be noted 
that glucose and cholesterol tests in women over 45 years 
of age should be performed every 5 years as a minimum. 
If any abnormalities are found, a 75 g OGTT and a full lipid 
profile test should be performed. Women with diabetes, im-
paired glucose tolerance, obesity, hypertension, and other 
risk factors for atherosclerosis should have the tests per-
formed at an appropriately higher frequency.
What is the recommended menopausal 
hormone therapy approach 
in hysterectomised women?
Menopausal hormone therapy in women after to-
tal/subtotal hysterectomy is based on the continuous 
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administration of a fixed dose of estrogen alone. In these 
women, there are no factors justifying the concurrent ad-
ministration of progestogen or breaks in hormone therapy.
What is the recommended menopausal 
hormone therapy approach in patients 
with premature ovarian insufficiency?
In women with premature ovarian insufficiency, sys-
temic MHT is recommended at least until the average 
age of the menopause in the general population.
Premature menopause affects 1% of women < 40 
years of age, and early menopause occurs in 5% of 
women < 45 years of age. The standard dose (equiv-
alent to 2 mg of E2 orally) is usually effective in elimi-
nating menopausal symptoms and reducing the risk of 
cardiovascular diseases and osteoporosis. The benefits 
of therapy are vast, and the safety profile is generally 
favorable.
What strategy should be used in patients 
with topical symptoms (e.g. vaginal 
dryness, dyspareunia, etc.) persisting 
despite systemic menopausal hormone 
therapy?
Symptoms of genitourinary syndrome of meno-
pause (GSM) include vaginal dryness, irritation, dysuria, 
dyspareunia and recurrent infections. Low-dose local 
estrogen therapy is more effective (80-90%) than gen-
eral systemic therapy (75%). However, it must be noted 
that such therapy fails to eliminate symptoms of GSM 
in approximately 30-40% of patients with indications 
for systemic MHT. In such cases, topical treatment 
(i.e. intravaginal administration of estriol or estradiol) 
should be considered an adjunct to systemic treatment. 
Topical therapy requires no supplementation with pro-
gestogen. Also, it is not subject to any time constraints 
regarding the initiation and duration of treatment.
Intravaginal products available in Poland act topi-
cally and have a  negligible or no systemic effect (es-
tradiol). It can be assumed that there are no absolute 
contraindications to local therapy of GSM. Concurrent 
administration of probiotics and/or topical hyaluronic 
acid products is recommended in patients with recur-
rent vaginitis secondary to atrophy.
Are there any effective alternatives to 
menopausal hormone therapy, such as 
plant-based therapies?
Menopausal hormone therapy is the most effec-
tive treatment modality for vasomotor symptoms in 
patients of any age, but the benefit-to-risk ratio is the 
greatest in patients in whom MHT was initiated under 
the age of 60 years or within 10 years after the last men-
struation. Only with respect to the initiation of therapy.
The latest meta-analyses show that studies investi-
gating the application of phytotherapy in menopausal 
medicine published to date have limited strength of 
evidence. This is due not only to the imperfect design 
of these studies, but also to the placebo effect which 
is particularly strongly marked in this therapeutic area. 
The conclusions of these meta-analyses should be in-
terpreted as the absence of unambiguous evidence for 
the efficacy of phytoestrogens but, at the same time, 
the absence of clear evidence for their inefficacy. The 
level of data reliability is slightly higher with respect to 
the tolerance and safety profile of phytoestrogen prod-
ucts. Most of the available studies addressing this top-
ic provide evidence that long-term therapy with these 
drugs is both well-tolerated and safe. However, the the-
sis on the complete oncological safety of phytoestro-
gens, especially soya, remains to be proven. 
The Expert Team of the Polish Menopause and An-
dropause Society has issued the following statement: 
“Phytoestrogens should be considered in women whose 
quality of life has been significantly impaired by meno-
pausal symptoms and who cannot or do not want to use 
menopausal hormone therapy involving systemic treat-
ment with estrogens and/or progestogens”. 
Who is authorized to issue prescriptions 
for menopausal hormone therapy drugs?
All doctors, including primary care physicians, are 
authorized to prescribe drugs for MHT. Since the avail-
ability of this therapy is still limited, it is important to 
ensure that as many physicians of different medical 
specialties as possible engage in the initiation/manage-
ment of MHT in low-risk patients.
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Appendix
Menopausal hormone therapy (estrogen-progestogen therapy) – drugs available in Poland
Ultra-low doses: 
0.5 mg E2 orally or 0.014 mg E2 transdermally
Oral therapy
Product Dosage form Composition and dose Type of therapy
Femoston mini Tablets 28 tablets: 0.5 mg E2
+ 2.5 mg DYD
Continuous
Low doses: 
1 mg E2 orally or 0.025-0.0375 mg E2 transdermally
Oral therapy
Product Dosage form Composition and dose Type of therapy
Novofem Tablets 16 tablets: 1 mg E2
+ 12 tablets:
1 mg E2 + 1 mg NETA
Sequential 
Femoston mite Tablets 14 tablets: 1 mg E2
+ 14 tablets:
1 mg E2 + 10 mg DYD 
Sequential 
Activelle Tablets 28 tablets
1 mg E2 + 0.5 mg NETA
Continuous
Cliovelle Tablets 28 tablets
1 mg E2 + 0.5 mg NETA
Continuous
Angeliq Tablets 28 tablets
1 mg E2 + 2 mg DRSP
Continuous
Vielbiene Mini Tablets 28 tablets
1 mg E2V + 2 mg DNG*
 Continuous
Femoston conti Tablets 28 tablets
1 mg E2 + 5 mg DYD
Continuous
Standard doses:
2 mg E2 orally or 0.05 mg E2 transdermally
Oral therapy
Product Dosage form Doses Type of therapy
Klimonorm Tablets 9 tablets: 2 mg E2V +
12 tablets: 2 mg E2V + 0.15 mg LNG
Sequential with 7-day break
Cyclo-Progynova Tablets 11 tablets: 2 mg E2V +
10 tablets: 2 mg E2V + 0.5 mg NOR
Sequential with 7-day break
Divina Tablets 11 tablets 2 mg E2V +
10 tablets: 2 mg E2V + 10 mg MPA
Sequential with 7-day break 
Trisequens Tablets 12 tablets: 2 mg E2 + 
10 tablets: 2 mg E2 + 1 mg NETA
Sequential  
Femoston Tablets 14 tablets 2 mg E2 + 
14 tablets: 2 mg E2 + 10 mg DYD
Sequential 
Transdermal therapy
Product Dosage form Doses Type of therapy
Systen Sequi Transdermal system –  
skin patches
4 patches releasing 
50 µg E2/24 h + 4 patches releasing 50 µg E2 
+ 170 µg NETA/24 h
Sequential 
Fem7 combi Transdermal system –  
skin patches
2 patches releasing
50 µg/24 h + 2 patches releasing
50 µg E2 + 10 µg LNG/24 h
Sequential
Systen Conti Transdermal system –  
skin patches
8 patches releasing
50 µg E2 + 170 µg NETA/24 h
Continuous
Estalis Transdermal system –  
skin patches
8 patches releasing 
50 µg E2 + 140 g NETA/24 h
Continuous
E2 – estradiol, DYD – dydrogesterone, E2V – estradiol valerate, DRSP – drospirenone, LNG – levonorgestrel, NOR – norgestrel, MPA – medroxyprogesterone 
acetate, *2 mg of estradiol valerate (E2V) is equivalent to 1.53 of estradiol (E2)
